Minovia Therapeutics gains FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Friday, September 19, 2025
Minovia Therapeutics has received Fast Track Designation from the US Food and Drug Administration (FDA) for its lead investigational therapy, MNV-201, in Myelodysplastic Syndrome (MDS).
MDS is an age-related blood disorder caused by ineffective blood cell production and genetic instability, which may progress to Acute Myeloid Leukaemia (AML). Patients often face a high symptom burden and an increased risk of complications. Minovia’s research suggests MDS may be linked to mitochondrial dysfunction, further supporting the company’s approach.
MNV-201 is a first-in-class cell therapy based on Minovia’s Mitochondrial Augmentation Technology (MAT). The treatment involves introducing healthy mitochondria into a patient’s own stem cells to restore energy production, organ function, and overall health. Early clinical studies in Pearson Syndrome have indicated safety and potential multi-system benefits.
This is the second FDA Fast Track recognition for MNV-201, which already holds Fast Track and Rare Paediatric Disease Designations for the treatment of Pearson Syndrome, a rare and life-threatening mitochondrial disorder affecting children. The therapy is currently under investigation in a Phase 2 clinical trial for Pearson Syndrome and a Phase Ib trial in low-risk MDS patients. Six of the nine planned patients in the MDS study have already been treated.
Fast Track Designation is intended to speed up the development and review of medicines for serious conditions with unmet medical needs. It provides opportunities for closer interaction with the FDA, eligibility for priority review, and the option of rolling submission for a future Biologics License Application.
The company has also announced a definitive business combination agreement with Launch One Acquisition Corp., a special purpose acquisition company.
Upon completion, expected in late 2025, the combined entity will continue as Minovia Therapeutics and list on Nasdaq under a new ticker symbol.
Source: globenewswire.com
